Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) major shareholder Paul B. Manning purchased 1,333,333 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the acquisition, the insider now owns 1,333,333 shares in the company, valued at $2,999,999.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Taysha Gene Therapies Stock Up 0.9 %
Shares of NASDAQ TSHA opened at $2.26 on Tuesday. The business has a 50-day moving average price of $2.97 and a 200 day moving average price of $2.43. The stock has a market cap of $422.66 million, a PE ratio of -4.61 and a beta of 0.50. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies, Inc. has a 52-week low of $0.61 and a 52-week high of $4.32.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. The business had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same period in the prior year, the company earned ($0.28) earnings per share. Equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Analysis on TSHA
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new stake in Taysha Gene Therapies in the third quarter worth about $58,373,000. RTW Investments LP acquired a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $53,382,000. Avoro Capital Advisors LLC boosted its holdings in shares of Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares in the last quarter. Acuta Capital Partners LLC acquired a new position in shares of Taysha Gene Therapies during the third quarter valued at approximately $12,096,000. Finally, Vanguard Group Inc. raised its holdings in Taysha Gene Therapies by 235.2% during the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after purchasing an additional 3,738,616 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
- Five stocks we like better than Taysha Gene Therapies
- 3 Small Caps With Big Return Potential
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Investing in Travel Stocks Benefits
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- The 3 Best Fintech Stocks to Buy Now
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.